Abstract
Mobilization of suitable amounts of PBSCs with granulocyte-CSF (G-CSF) can be difficult in children. We report the results of using plerixafor in pediatric patients who failed to mobilize progenitors with G-CSF-based regimens. Thirty-three patients, median age 9 years (range 1–18 years) and median weight 29 kg (range 10–85 kg) were enrolled into the study. After 4 days of G-CSF stimulation, the median CD34+ cell count in peripheral blood was 10.4 per μL (range 0.27–23.0 per μL). Plerixafor was administered subcutaneously (0.24 μg/kg in 30 patients and 0.3 μg/kg in 3 patients) 11–12 h before apheresis. At the time of apheresis, CD34+ cell counts increased to a median of 44.1 per μL (range 8.4–357.0 per μL), a median 4.4-fold increase. Two patients (6%) failed to mobilize. Thirty-one patients underwent apheresis and in 27 >2 × 106 CD34+ cells per kg of body weight were collected after one procedure. In total, 31 of 33 patients mobilized successfully and the median number of cryopreserved CD34+ cells was 5.6 × 106 /kg body weight (2.7 × 106–27.4 × 106). Twenty-four patients underwent transplantation. Engraftment was achieved in all but one patient, who died on day +9 after hematopoietic stem cell transplantation. The median time of neutrophil and platelet recovery was day +12 and +16, respectively. Our study confirms that plerixafor has impressive efficacy and very modest toxicity in children.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Baldomero H, Gratwohl M, Gratwohl A, Tichelli A, Niederwieser D, Madrigal A et al. The EBMT activity survey 2009: trends over the past 5 years. Bone Marrow Transplant 2011; 46: 485–501.
Kuittinen T, Nousiainen T, Halonen P, Mahlamäki E, Jantunen E . Prediction of mobilization failure in patients with non-Hodgkin's lymphoma. Bone Marrow Transplant 2004; 33: 907–912.
Ferraro F, Lymperi S, Méndez-Ferrer S, Saez B, Spencer JA, Yeap BY et al. Diabetes impairs hematopoietic stem cell mobilization by altering niche function. Sci Transl Med 2011; 3: 104ra101.
Gertz MA, Wolf RC, Micallef INM, Gastineau DA . Clinical impact and resource utilization after stem cell mobilization failure in patients with multiple myeloma and lymphoma. Bone Marrow Transplant 2010; 45: 1396–1403.
Hosing C, Saliba RM, Ahlawat S, Körbling M, Kebriaei P, Alousi A et al. Poor hematopoietic stem cell mobilizers: a single institution study of incidence and risk factors in patients with recurrent or relapsed lymphoma. Am J Hematol 2009; 84: 335–337.
Molineux G, Pojda Z, Hampson IN, Lord BI, Dexter TM . Transplantation potential of peripheral blood stem cells induced by granulocyte colony-stimulating factor. Blood 1990; 76: 2153–2158.
Devine SM, Flomenberg N, Vesole DH, Liesveld J, Weisdorf D, Badel K et al. Rapid mobilization of CD34+ cells following administration of the CXCR4 antagonist AMD3100 to patients with multiple myeloma and non-Hodgkin's lymphoma. J Clin Oncol 2004; 22: 1095–1102.
Fowler CJ, Dunn A, Hayes-Lattin B, Hansen K, Hansen L, Lanier K et al. Rescue from failed growth factor and/or chemotherapy HSC mobilization with G-CSF and plerixafor (AMD3100): an institutional experience. Bone Marrow Transplant 2009; 43: 909–917.
Devine SM, Vij R, Rettig M, Todt L, McGlauchlen K, Fisher N et al. Rapid mobilization of functional donor hematopoietic cells without G-CSF using AMD3100, an antagonist of the CXCR4/SDF-1 interaction. Blood 2008; 112: 990–998.
Fruehauf S, Veldwijk MR, Seeger T, Schubert M, Laufs S, Topaly J et al. A combination of granulocyte-colony-stim- ulating factor (G-CSF) and plerixafor mobilizes? more primitive peripheral blood progenitor cells? than G-CSF alone: results of a European phase II? study. Cytotherapy 2009; 11: 992–1001.
Fruehauf S . Current clinical indication for plerixafor. Transfus Med Hemother 2013; 40: 246–250.
Emir S, Demir HA, Aksu T, Kara A, Özgüner M, Tunç B . Use of plerixafor forperipheral blood stem cell mobilization failure in children. Transfus Apher Sci 2014; 50: 214–218.
Hong KT, Kang HJ, Kim NH, Kim MS, Lee JW, Kim H et al. Successful mobilization using a combination of plerixafor and G-CSF in pediatric patients who failed previous chemomobilization with G-CSF alone and possible complications of the treatment. J Hematol Oncol 2012; 5: 14.
Vettenranta K, Möttönen M, Riikonen P . The use of plerixafor in harvesting autologous stem cells in the pediatric setting. Pediatr Blood Cancer 2012; 59: 197–198.
Modak S, Cheung IY, Kushner BH, Kramer K, Reich L, Cheung NK . Plerixafor plus granulocyte-colony stimulating factor for autologous hematopoietic stem cell mobilization in patients with metastatic neuroblastoma. Pediatr Blood Cancer 2012; 58: 469–471.
Toledano H, Yahel A, Cohen IJ, Yaniv I, Stein J . Successful mobilization,harvest and transplant of peripheral blood stem cells using AMD3100 and G-CSFfollowing high dose craniospinal irradiation for medulloblastoma in a young child. Pediatr Blood Cancer 2010; 54: 613–615.
Aabideen K, Anoop P, Ethell ME, Potter MN . The feasibility of plerixafor as a second-line stem cell mobilizing agent in children. J Pediatr Hematol Oncol 2011; 33: 65–67.
McCullough J, Clay M, Herr G, Smith J, Stroncek D . Effects of granulocyte-colony-stimulating factor on potential normal granulocyte donors. Transfusion 1999; 39: 1136–1140.
Choi S, Rajan SS, Trivedi MV . The incidence of tumor cell contamination of peripheral blood stem cells: a meta-analysis to evaluate the impact of mobilization regimens and the influence on outcomes in breast cancer patients. Acta Haematol 2014; 131: 133–140.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
AAM has received speaker’s fees from Sanofi during previous years for educational lectures not concerning topic of the presented study. The remaining authors declared no conflict of interest.
Rights and permissions
About this article
Cite this article
Maschan, A., Balashov, D., Kurnikova, E. et al. Efficacy of plerixafor in children with malignant tumors failing to mobilize a sufficient number of hematopoietic progenitors with G-CSF. Bone Marrow Transplant 50, 1089–1091 (2015). https://doi.org/10.1038/bmt.2015.71
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/bmt.2015.71
This article is cited by
-
Development and validation of a predictive model to guide the use of plerixafor in pediatric population
Bone Marrow Transplantation (2022)
-
Plerixafor combined with standard regimens for hematopoietic stem cell mobilization in pediatric patients with solid tumors eligible for autologous transplants: two-arm phase I/II study (MOZAIC)
Bone Marrow Transplantation (2020)